|
Quotes & Info
|
| ISIS > SEC Filings for ISIS > Form 8-K on 21-Oct-2009 | All Recent SEC Filings |
21-Oct-2009
Other Events, Financial Statements and Exhibits
On October 21, 2009, Isis Pharmaceuticals, Inc. ("Isis") announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. A copy of the Press Release related to these data is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(d) Exhibits.
99.1 Press Release dated October 21, 2009.
|
|